Skip to main content

Table 3 Treatment and outcomes (n = 25)

From: Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment

Characteristic Value
Hospitalization, n (%) 15 (60)
Duration of hospitalization, days (IQR) 7 (3–11)
Cholecystitis was the reason to stop ICI treatment, n (%) 3 (12)
Treatment, n (%)
 Intravenous fluid 17 (68)
 Antibiotics 18 (72)
 Steroids 5 (20)
 Surgical cholecystectomy 5 (20)
 Percutaneous drainage 8 (32)
Complications, n (%)
 Sepsis 2 (8)
 Perforation 4 (16)
Restarted ICI therapy after onset, n (%) 10 (40)
Recurrent cholecystitis symptoms, n (%) 0 (0)
Any-cause death, n (%)a 12 (48)
  1. aDeaths recorded were unrelated to cholecystitis. IQR interquartile range, ICI immune checkpoint inhibitor